Aprepitant for the prevention of chemotherapy-induced nausea and vomiting in children: A randomised, double-blind, phase 3 trial

The Lancet Oncology

Volumn 16, Issue 4, 2015, Pages 385-394

  Kang, Hyoung Jin ^a   Loftus, Susan ^b   Taylor, Arlene ^b   DiCristina, Cara ^b   Green, Stuart ^b   Zwaan, Christian Michel ^c  

^a Seoul National University College of Medicine   (South Korea)

^b MERCK RESEARCH LABORATORIES   (United States)

^c SOPHIA CHILDREN S HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

APREPITANT; DEXAMETHASONE; MORPHOLINE DERIVATIVE;

ADOLESCENT; ADULT; ADVERSE EFFECTS; CHEMICALLY INDUCED; CHILD; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMAN; INDUCTION CHEMOTHERAPY; INFANT; MALE; NAUSEA; NEOPLASMS; PATHOLOGY; PHASE 3 CLINICAL TRIAL; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; VOMITING;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; DEXAMETHASONE; DOUBLE-BLIND METHOD; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; INDUCTION CHEMOTHERAPY; INFANT; MALE; MORPHOLINES; NAUSEA; NEOPLASMS; VOMITING;

EID: 84930240637     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(15)70061-6     Document Type: Article

References (24)

1. NCCN clinical practice guidelines in oncology. Antiemesis. Version 1 National Comprehensive Cancer Network, (accessed Oct 8, 2014). http://www.nccn.org/professionals/physician_gls/PDF/antiemesis.pdf.
2. MASCC/ESMO antiemetic guideline Multinational Association of Supportive Care in Cancer, (accessed Oct 8, 2014). http://www.mascc.org/antiemetic-guidelines.
3. Basch E, Prestrud AA, Hesketh PJ, et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2011, 29:4189-4198.
4. Small BE, Holdsworth MT, Raisch DW, Winter SS Survey ranking of emetogenic control in children receiving chemotherapy. J Pediatr Hematol Oncol 2000, 22:125-132.
5. Holdsworth MT, Raisch DW, Frost J Acute and delayed nausea and emesis control in pediatric oncology patients. Cancer 2006, 106:931-940.
6. Dupuis LL, Nathan PC Optimizing emetic control in children receiving antineoplastic therapy: beyond the guidelines. Paediatr Drugs 2010, 12:51-61.
7. LeBaron S, Zeltzer LK, LeBaron C, Scott SE, Zeltzer PM Chemotherapy side effects in pediatric oncology patients: drugs, age, and sex as risk factors. Med Pediatr Oncol 1988, 16:263-268.
8. EMEND (aprepitant) capsules, for oral use 2013, Merck Sharp & Dohme Corp, Whitehouse Station, NJ.
9. Andrews PL, Bhandari P The 5-hydroxytryptamine receptor antagonists as antiemetics: preclinical evaluation and mechanism of action. Eur J Cancer 1993, 29A(suppl 1):S11-S16.
10. Tattersall FD, Rycroft W, Hill RG, Hargreaves RJ Enantioselective inhibition of apomorphine-induced emesis in the ferret by the neurokinin1 receptor antagonist CP-99,994. Neuropharmacology 1994, 33:259-260.
11. Tattersall FD, Rycroft W, Francis B, et al. Tachykinin NK1 receptor antagonists act centrally to inhibit ernesis induced by the chemotherapeutic agent cisplatin in ferrets. Neuropharmacology 1996, 35:1121-1129.
12. Hesketh PJ, Grunberg SM, Gralla RJ, et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin-the Aprepitant Protocol 052 Study Group. J Clin Oncol 2003, 21:4112-4119.
13. Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, et al. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 2003, 97:3090-3098.
14. Warr DG, Hesketh PJ, Gralla RJ, et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol 2005, 23:2822-2830.
15. Supportive care of children with cancer 2004, The Johns Hopkins University Press, Baltimore, MD. 3rd edn. A.J. Altman (Ed.).
16. Companion handbook to the chemotherapy source book 2004, Lippincott Williams & Wilkins, Baltimore, MD. 2nd edn. M.C. Perry, C.M. Anderson, D.C. Doll, V. Malhotra, N. Shahab, J.E. Wooldridge (Eds.).
17. Nakade S, Ohno T, Kitagawa J, et al. Population pharmacokinetics of aprepitant and dexamethasone in the prevention of chemotherapy-induced nausea and vomiting. Cancer Chemother Pharmacol 2008, 63:75-83.
18. Aapro MS, Walko CM Aprepitant: drug-drug interactions in perspective. Ann Oncol 2010, 21:2316-2323.
19. Gore L, Chawla S, Petrilli A, et al. Aprepitant in adolescent patients for prevention of chemotherapy-induced nausea and vomiting: a randomized, double-blind, placebo-controlled study of efficacy and tolerability. Pediatr Blood Cancer 2009, 52:242-247.
20. Common terminology criteria for adverse events v4.0 (CTCAE). Cancer Therapy Evaluation Program, common terminology for adverse events, version 30. 5-28-2009 2009, US Department of Health and Human Services, National Cancer Institute, Bethesda, MD.
21. Miettinen O, Nurminen M Comparative analysis of two rates. Stat Med 1985, 4:213-226.
22. Nunn T, Williams J Formulation of medicines for children. Br J Clin Pharmacol 2005, 59:674-676.
23. de Wit R, Hesketh PJ, Warr D The oral NK1 antagonist aprepitant for prevention of nausea and vomiting in patients receiving highly emetogenic chemotherapy: a review. Am J Cancer 2005, 4:35-48.
24. Schmoll HJ, Aapro MS, Poli-Bigelli S, et al. Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment. Ann Oncol 2006, 17:1000-1016.